AU3614493A - Non-toxic lipid vaccine formulations - Google Patents
Non-toxic lipid vaccine formulationsInfo
- Publication number
- AU3614493A AU3614493A AU36144/93A AU3614493A AU3614493A AU 3614493 A AU3614493 A AU 3614493A AU 36144/93 A AU36144/93 A AU 36144/93A AU 3614493 A AU3614493 A AU 3614493A AU 3614493 A AU3614493 A AU 3614493A
- Authority
- AU
- Australia
- Prior art keywords
- vaccine formulations
- toxic lipid
- lipid vaccine
- toxic
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US885905 | 1986-07-15 | ||
US83061292A | 1992-02-04 | 1992-02-04 | |
US830612 | 1992-02-04 | ||
US88590592A | 1992-05-18 | 1992-05-18 | |
US94263992A | 1992-09-09 | 1992-09-09 | |
US942639 | 1992-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3614493A true AU3614493A (en) | 1993-09-01 |
Family
ID=27420220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU36144/93A Abandoned AU3614493A (en) | 1992-02-04 | 1993-02-04 | Non-toxic lipid vaccine formulations |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3614493A (en) |
WO (1) | WO1993014744A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795870A (en) * | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
US5693769A (en) * | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
EP0734251B1 (en) * | 1993-12-17 | 2009-10-14 | Novavax, Inc. | Method of transmitting a biologically active material to a cell |
FR2726764B1 (en) * | 1994-11-14 | 1997-01-31 | Pasteur Merieux Serums Vacc | ADJUVANT FOR VACCINE COMPOSITION |
EP0902682A2 (en) | 1996-05-08 | 1999-03-24 | Nika Health Products Limited | Cationic virosomes as transfer system for genetic material |
CU23313A1 (en) * | 2002-11-27 | 2008-09-25 | Inst Finlay Ct De Investigacia | MÃ0 / 00 METHOD OF OBTAINING COCLEAR STRUCTURES VACCINAL COMPOSITIONS AND ADJUSTS BASED ON COCLEAR STRUCTURES AND THEIR INTERMEDIARIES |
WO2005041932A2 (en) * | 2003-11-03 | 2005-05-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for selecting cationic or anionic liposomes for treatment of a mucosa membrane, and kit comprising the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5049386A (en) * | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
NZ230424A (en) * | 1988-08-25 | 1992-05-26 | Liposome Co Inc | Liposomal composition comprising an externally disposed antigen |
-
1993
- 1993-02-04 AU AU36144/93A patent/AU3614493A/en not_active Abandoned
- 1993-02-04 WO PCT/US1993/001102 patent/WO1993014744A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1993014744A1 (en) | 1993-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL101290A0 (en) | Vaccine formulations | |
AU8131191A (en) | Sustained release formulations | |
AU1802492A (en) | New aqueous formulations | |
AU8554691A (en) | Improved formulations | |
AU1218892A (en) | Pharmaceutical aerosol formulations | |
AU3049392A (en) | Underarm formulations containing alkylmethylsiloxanes | |
GB9207832D0 (en) | Formulations | |
AU8289891A (en) | Improved antiperspirant formulations | |
AU8039591A (en) | Gel formulations | |
AU8130391A (en) | Solid formulations | |
GB9118830D0 (en) | Medical aerosol formulations | |
AU3154395A (en) | Contraceptive vaccine | |
AU1247192A (en) | Steroid formulations | |
AU2769595A (en) | Contraceptive vaccine | |
GB9214390D0 (en) | Formulations | |
AU3614493A (en) | Non-toxic lipid vaccine formulations | |
IL117670A0 (en) | Low dose ridogrel formulations | |
AU4450696A (en) | Enhanced immunogenic vaccine | |
GB9201639D0 (en) | Pharmaceutical formulations | |
AU4970193A (en) | IPNV vaccine | |
AU641509B2 (en) | Gemfibrozil formulations | |
AU634086B2 (en) | Gemfibrozil formulations | |
AU1851392A (en) | Ccv vaccine | |
AU663388B2 (en) | Sustained release formulations | |
AU1001397A (en) | Sustained release capsule and formulations |